Purpose Sphingosine kinase is an oncogene that is upregulated in several solid tumors. The product of the sphingosine kinase activity, sphingosine-1-phosphate is a potent mitogen involved in diverse cell processes such as cell survival and migration. Current standard therapy in the treatment of glioblastoma multiforme (GBM) is a combination of surgery, radiation, and chemotherapy using the drug temozolomide (TMZ). However, virtually all tumors become resistant to TMZ. Therefore, new drug targets are necessary. In this study, we investigated whether inhibiting sphingosine kinase could induce cell death in TMZ-resistant GBM cells. Methods To study TMZ resistance in vitro, we have generated TMZ-resistant cell lines from established GBM cells. We used a potent inhibitor of sphingosine kinase to study its eVect on colony formation and cell growth in GBM cells with a limited dilution and WST assay. Moreover, cell death was determined by measuring caspase-3 activity using Xow cytometry. Results A sphingosine kinase inhibitor reduced cell colony formation and activated caspase-3 in both TMZsensitive and resistant GBM cells. Conclusion Addition of a sphingosine kinase inhibitor to the standard chemotherapy regimen against GBM may be beneWcial.
Introduction
Glioblastoma multiforme (GBM) is among the most aggressive solid tumors [1] . In recent years, little signiWcant progress in new therapies has been made. One of the most signiWcant advancements in treating GBM has been the introduction of the chemotherapeutic drug temozolomide (TMZ) which has been shown to provide a survival beneWt for GBM patients when used in combination with surgery and radiation. While the initial treatment of many GBM with TMZ shows dramatic results, virtually all tumors recur and become resistant to this drug. Thus, the identiWcation of new drug targets is essential for developing eVective therapies against GBM.
Sphingosine-1-phosphate (S1P) has emerged as a potent lipid signaling molecule that plays a role in many biological processes such as cell survival, mitogenesis and cell migration [2] . S1P has a central role in T cell traYcking and maturation which was discovered by studies involving the immunosuppressant drug FTY720. FTY720 was developed as an analog of myriocin. Further investigations on the action of FTY720 revealed that the drug is phosphorylated in vivo and acts as an agonist to the S1P 1 receptor and thereby altering the T cell biology. Currently, FTY720 is tested in clinical trials as an immunosuppressant in organ transplant rejection and multiple sclerosis [3] . Moreover, the enzyme sphingosine kinase 1 (Sphk1) that produces S1P, has been implicated in cancer as many tumors show an increased expression when compared to the matching normal tissues [4] . Recently, Paugh et al. [5] demonstrated that the proinXammatory cytokine IL-1 which is secreted by multiple GBM cell lines can regulate Sphk1 expression. Sphk1 is considered an oncogene due to its ability to induce colony formation in soft agar [6] . In vitro, S1P has been shown to be a strong signal for cell proliferation in diVerent cell types [7] .
Of relevance to our study, Van Brocklyn et al. [8] have shown a correlation between Sphk1 expression in GBM tissues and poor patient prognosis. Moreover, Anelli et al. [9] have demonstrated that hypoxia-inducible factor (HIF) controls Sphk1 expression in glioblastoma cells. Using microarray analysis to compare the gene expression proWle of GBM cells sensitive and resistant to TMZ, we observed an increase in Sphk1 gene expression. Therefore, to study the eVect of Sphk1 on GBMs we have used a recently published and commercially available inhibitor of Sphk1, 2-(p-hydroxyanilino)-4-(p-chlorophenyl)thiazole (referred to as SKI = sphk1 inhibitor) [4] . In the present paper, we demonstrate that SKI inhibits colony formation of both TMZ sensitive and resistant cells as measured in a limiting dilution assay. Moreover, it induced apoptotic cell death in both TMZ sensitive and resistant cell lines. Laboratory generated resistance to TMZ Cells were initially cultured in the presence of 10 M of TMZ and 25 M O 6 -BG. After every three passages, the concentration of TMZ was increased 5-10 M. The resulting resistant cell lines are denoted as O 6 -BG and TMZ resistance (OTR) and the sensitive lines as P (parental).
Methods

Drug
Drug treatments
All treatments of U251 cells with TMZ were done in the presence of 20 M O 6 -BG to pharmacologically ablate the DNA repair enzyme, methylguanine-methyltransferase (MGMT). Treatment of D54MG cells with TMZ did not include O 6 -BG as these cells do not express detectable amounts of MGMT. Treatment of cells with SKI was done in medium containing 10% charcoalstripped FBS (Invitrogen) due to the Wnding that serum contains a signiWcant amount of S1P, the product of Sphk1 [10] . Only the long-term limiting dilution assays with SKI were performed in medium containing normal FBS.
Real-time quantitative RT-PCR
RNA was isolated from cells using RNeasy kit (Qiagen) and 1-1.5 g was converted to cDNA using the Superscript First Strand Synthesis System from Invitrogen. TaqMan Gene Expression Assays for Sphk1 (cat# Hs01116528_m1) and GAPDH (cat# Hs99999905_m1) were purchased from Applied Biosystems. The PCR reactions were run on an 7900HT Real-Time PCR System (Applied Biosystems) with the following program: 50°C, 2 min; 95°C, 10 min; 95°C, 15 s (40 cycles); 60°C, 1 min.
Limiting dilution assay
The limiting dilution assay was executed exactly as described previously [11] . BrieXy, cells were harvested in exponential growth and treated at a density of 10 6 cells/ml with SKI (concentrations, 3, 5, 10, 20, 30, 40, 60 M). Serial Wvefold dilutions (with medium containing SKI at the respective concentration) were made from each original tube, and 100 l were plated per well in a 96-well Xat-bottomed tissue culture plate (6 wells/dilution, 8 dilutions/ original tube). The plates were incubated at 37°C in a humidiWed atmosphere of 5% CO 2 for 12 days, and the wells were examined for colony formation (>30 cells), using an inverted microscope. Each well was scored as positive or negative for the presence of colonies.
Cell proliferation assay
Cell proliferation was estimated by measuring metabolic activity performed using the Cell Counting Kit 8 (Dojindo) which uses a WST compound. Cells were plated at 5,000-10,000 cells per well in a 96-well plate. After 24 h, medium was aspirated and cells incubated with SKI for 48 h. After incubation, WST-8 reagent was added and cells incubated for an additional 1-2 h at 37°C. Absorbance was read at 450 nm.
Measurement of caspase-3 activity by Xow cytometry U251P and U251-OTR cells were treated with 100 M TMZ or 20 M of SKI. After 72 h, the activation status of caspase-3 was measured on BD FACSCalibur using the caspase-3, Active Form kit (BD Pharmingen) according to the manufacturer's instructions.
Result
In order to study resistance mechanisms and design new drug targets in GBM, we have generated cell lines that are resistant to TMZ in the presence of O 6 -BG. The presence of the O 6 -BG precluded resistance caused by elevation of MGMT expression. Both the parental and OTR cells of the GBM cell lines U251 and D54MG are DNA mismatch repair proWcient (data not shown). As shown in Fig. 1a, b , TMZ had relatively little eVect on colony formation in the OTR lines even in the presence of O 6 -BG. A microarray analysis comparing U251P and U251-OTR revealed a 4.8-fold up-regulation of Sphk1 gene expression. Sphk2 gene expression was not altered. Other genes involved in sphingolipid metabolism and signaling that were changed more than twofold in U251-OTR versus U251P were the S1P receptor isoform 1 (3.2-fold increase) and the LAG1 (longevity assurance gene) homolog ceramide synthase 6 (twofold decrease). To conWrm the result with the Sphk1 gene, we measured the Sphk1 RNA levels by real-time RT-PCR in the TMZ sensitive and resistant U251 and D54MG cells. In both instances, we observed an increase in the Sphk1 RNA expression in the OTR cells relative to the parental cells (Fig. 1c) : approximately threefold for U251-OTR and twofold for D54MG-OTR.
To determine the eVect of inhibition of Sphk1 on U251 and D54MG cells, we treated the cells with Sphk1 inhibitor, SKI, and measured colony formation. We observed that SKI inhibited colony formation in both the P and OTR lines of U251 and D54MG to a similar extent (Fig. 2a, b) . The calculated LD 10 's for SKI in U251P, U251-OTR, D54MG, and D54MG-OTR were 11.2 § 0.7, 12.9 § 2.0, 10.3 § 1.8, and 10.0 § 2.7 M, respectively. To examine the short term eVects of SKI, we carried out cell proliferation assays as shown in Fig. 2c, d . After 48 h incubation, SKI signiWcantly inhibited cell growth in all the cell lines.
Temozolomide has been found to cause cell-cycle inhibition and cell death in glioma cells [12, 13] . TMZ causes the methylation of DNA at N 7 guanine, N 3 adenine and O 6 guanine, whereby the latter methylation is critical for TMZ's cytotoxicity. Methylated O 6 guanine incorrectly pairs with thymine which triggers the mismatch repair system. The repair attempts fail leading to the reinsertion of thymine. The repetitive and futile attempts to repair the mismatch leads ultimately to DNA strand breaks, growth arrest and cell death [14] . When U251P cells were treated with 100 M TMZ, we observed a signiWcant proportion of the cells in apoptosis as quantiWed by caspase-3 activation (Fig. 2e) . In contrast, U251-OTR cells showed no caspase-3 activation following TMZ treatment (Fig. 2e) . In contrast, when U251P or OTR cells were treated with SKI, we observed caspase-3 activation in both the TMZ sensitive and resistant cells. A similar result was observed for the D54MG cells (data not shown).
Discussion
Our initial undertaking was to study the role of Sphk1 in TMZ-mediated resistance. The impetus for this was the Wnding that U251-OTR and D54MG-OTR cells expressed higher amounts of Sphk1 RNA. However, when we inhibited Sphk1, we found a similar cytotoxic eVect on the parental and TMZ-resistant cells.
Sphingosine kinase 1 is a well-known lipid mediator in cell survival and apoptosis resistance. For example, melanoma cells that were resistant to cell death induction by CD95 antigen showed a higher expression of this lipid enzyme [15] . Down-regulation of Sphk1 rendered resistant melanoma cells susceptible to CD95-induced cell death.
Glioblastoma multiforme are hypoxic in the center of the tumor. Consequently, HIFs are stabilized which in turn up-regulate many of their target genes such as vascular endothelial growth factor (VEGF) that lead to tumor cell survival and tumor progression [16] . Recently, it was published that hypoxia induces Sphk1 expression and activity [9] . It is therefore conceivable that expression of Sphk1 may contribute to an aggressive and drug-resistant tumor phenotype. For example, it has been shown that S1P increases invasiveness of GBM cells [17] .
Sphingosine-1-phosphate, the product of Sphk1 is as potent a mediator of angiogenesis as VEGF [18, 19] . S1P exerts its angiogenic properties primarily through its speciWc receptor S1P 1 which was also signiWcantly upregulated in U251OTR cells [2] . Moreover, it has previously been shown that there is a crosstalk between S1P and wellknown pro-angiogenic growth factors such as VEGF, EGF, PDGF, bFGF and pro-angiogenic cytokines such as IL-6 and IL-8 leading to a positive signaling loop [20] . SpeciWcally, Sphk1 is a downstream target of all the above mentioned growth factors.
Anti-VEGF antibodies such as bevacizumab have shown promising results in clinical trials for the treatment of recurrent GBM [21] . It is possible that a limiting factor for the eYcacy of anti-VEGF antibody treatment may be that S1P produced by Sphk1 replaces VEGFs role in angiogenesis. Recently, Visentin et al. [19] have demonstrated that using antibodies against S1P can reduce or even diminish tumors in mouse models. Furthermore, the inhibition of tumor growth is likely mediated by the anti-angiogenic and antitumorigenic properties of the anti-S1P antibody [19] . It will be important to determine if inhibition of Sphk1 has an eVect on GBM mouse xenografts since inhibitors were observed to have an antitumor eVect in a murine adenocarcinoma [22] . A likely explanation for sphingosine kinase inhibitors to reduce cell proliferation and induce cell death may be the increase in the levels of sphingosine and/or its subsequent conversion to ceramide when Sphk1 activity is blocked. Both sphingosine and ceramide have been strongly implicated in apoptotic cell death in many cell types [2] .
In conclusion, it becomes increasingly clear that any treatment of a cancer as complex in its biology as GBM will require the targeting of multiple targets. Our results indicate that Sphk1 may prove to be one of these.
